Percentage of excess body mass index loss and cardiometabolic risk reduction in Peruvian adults undergoing sleeve gastrectomy. (May 2023)

• Record Type: Journal Article
• Authors: Bardelli, María Luisa; Neciosup-Leon, Marycielo; Castilla-Espinoza, Carlos S.; Torres-Pesantes, Luciana; Rodrigo-Gallardo, Paola K.; Huamanchumo-Suyon, Medalit E.; Bendezu-Quispe, Guido; Salinas-Sedo, Gustavo; Toro-Huamanchumo, Carlos J.
• Is Part Of: Obesity medicine. Volume 39(2023)
• Publication Date: 2023-05
• Subjects: Body mass index -- Metabolic syndrome -- Cardiovascular diseases -- Bariatric surgery -- Peru; Obesity -- Periodicals; Obesity; Obesity; Periodicals; Periodicals; 616.398005
• DOI: 10.1016/j.obmed.2023.100488
• Languages: English
• ISSNs: 2451-8476

Abstract

Abstract: Objective: To assess the association between the percentage of excess body mass index loss (%EBMIL) and cardiometabolic risk reduction in Peruvian adults undergoing laparoscopic sleeve gastrectomy (LSG). Methods: Retrospective cohort study conducted with adult patients who underwent LSG in a bariatric clinic during 2016–2020. The outcome variable was cardiometabolic risk change (expressed in Δ) 1 year after LSG. To that effect, the variables total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, very LDL (VLDL) cholesterol, triglycerides, glucose, insulin, and HOMA-IR at baseline and after 12 months were considered. The exposure variable was %EBMIL. Crude and adjusted β coefficients were estimated with linear regression models. Results: Of the 110 patients analyzed, 68.2% were women, and the median patient age was 34.5 years. In the model adjusted for sex, age, and baseline BMI, we noted that each 25% increase in %EBMIL resulted in a decrease in the values for total cholesterol, LDL, triglycerides, and insulin by 10.36 mg/dL (p < 0.001), 7.98 mg/dL (p = 0.001), 13.35 mg/dL (p = 0.033), and 3.63 uU/mL (p = 0.040), respectively. Conclusion: %EBMIL was associated with a decrease in total cholesterol, LDL, triglycerides, and insulin levels, which could suggest a favorable cardiometabolic evolution during the first 12 months following LSG. Highlights: Biomarkers significantly improve in the first 12 months following sleeve gastrectomy. %EBMIL was associated with a decrease in some biomarkers of cardiometabolic risk. Prospective assessment of patients covering a more extended period, is encouraged.